Sawgrass Asset Management LLC Buys Shares of 3,410 Amedisys Inc (AMED)

Share on StockTwits

Sawgrass Asset Management LLC bought a new position in Amedisys Inc (NASDAQ:AMED) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 3,410 shares of the health services provider’s stock, valued at approximately $399,000.

Several other large investors also recently bought and sold shares of the company. First Hawaiian Bank lifted its position in shares of Amedisys by 45.6% in the 4th quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after purchasing an additional 130 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Amedisys by 1.8% in the 4th quarter. State of Alaska Department of Revenue now owns 9,723 shares of the health services provider’s stock worth $1,138,000 after purchasing an additional 175 shares during the period. Creative Planning lifted its position in shares of Amedisys by 10.1% in the 4th quarter. Creative Planning now owns 2,264 shares of the health services provider’s stock worth $265,000 after purchasing an additional 207 shares during the period. Meeder Asset Management Inc. lifted its position in shares of Amedisys by 107.4% in the 4th quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock worth $56,000 after purchasing an additional 247 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amedisys by 15.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock worth $223,000 after purchasing an additional 251 shares during the period. 92.49% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Michael Paul North sold 5,625 shares of Amedisys stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $117.57, for a total value of $661,331.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Christopher Gerard sold 7,892 shares of Amedisys stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $119.02, for a total transaction of $939,305.84. Following the completion of the sale, the chief operating officer now owns 29,429 shares of the company’s stock, valued at $3,502,639.58. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,504 shares of company stock valued at $5,097,466. 2.60% of the stock is owned by company insiders.

Several research firms have recently commented on AMED. Benchmark cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $136.64 target price for the company. in a research report on Tuesday. Zacks Investment Research raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a research report on Tuesday, January 29th. ValuEngine raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday. SunTrust Banks increased their price target on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Finally, Craig Hallum lowered shares of Amedisys from a “buy” rating to a “hold” rating and decreased their price target for the stock from $116.00 to $104.00 in a research note on Friday, October 26th. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Amedisys presently has a consensus rating of “Buy” and an average target price of $113.97.

NASDAQ:AMED opened at $135.16 on Thursday. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of 61.16, a PEG ratio of 1.83 and a beta of 1.43. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. Amedisys Inc has a fifty-two week low of $54.06 and a fifty-two week high of $140.91.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4133977/sawgrass-asset-management-llc-buys-shares-of-3410-amedisys-inc-amed.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Article: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Monarch Partners Asset Management LLC Increases Position in Old Line Bancshares, Inc.
Monarch Partners Asset Management LLC Increases Position in Old Line Bancshares, Inc.
Monarch Partners Asset Management LLC Purchases New Holdings in Innovative Industrial Properties Inc
Monarch Partners Asset Management LLC Purchases New Holdings in Innovative Industrial Properties Inc
Opus Capital Group LLC Boosts Holdings in SYNNEX Co.
Opus Capital Group LLC Boosts Holdings in SYNNEX Co.
National Bank Financial Weighs in on Canadian Western Bank’s Q3 2019 Earnings
National Bank Financial Weighs in on Canadian Western Bank’s Q3 2019 Earnings
CIELO S A/S  To Go Ex-Dividend on February 21st
CIELO S A/S To Go Ex-Dividend on February 21st
Imperial Brands PLC  To Go Ex-Dividend on February 21st
Imperial Brands PLC To Go Ex-Dividend on February 21st


Leave a Reply

© 2006-2019 Ticker Report